TECELRA Receives Full FDA Approval, Expands Access to Adolescents with Synovial Sarcoma

TECELRA Receives Full FDA Approval, Expands Access to Adolescents with Synovial Sarcoma

June 26, 2026

US WorldMeds® announced that the U.S. Food and Drug Administration has granted full approval to TECELRA® (afamitresgene autoleucel), with an expanded indication that now includes eligible patients as young as 12 years old. The therapy, which received its original accelerated approval in August 2024, remains…

Synovial Sarcoma Foundation Announces Formation of Medical Advisory Board

Synovial Sarcoma Foundation Announces Formation of Medical Advisory Board

June 22, 2026

11 Leading Oncologists and Researchers Unite to Accelerate Progress for Synovial Sarcoma Patients PHILADELPHIA [June 22, 2026] The Synovial Sarcoma Foundation (SSF) today announced the formation of its Medical Advisory Board, bringing together 11 internationally recognized clinicians and researchers to serve as the central coordinating…

Breaking Down Synovial Sarcoma’s Defenses: A study on Immune Evasion and Targeted Treatment

Breaking Down Synovial Sarcoma’s Defenses: A study on Immune Evasion and Targeted Treatment

June 10, 2026

A landmark study from Jerby-Arnon, Neftel, Shore, and colleagues at the Broad Institute of Harvard and MIT, Massachusetts General Hospital, Dana-Farber Cancer Institute, and the University of Lausanne used single-cell RNA sequencing to profile 16,872 individual cells from 12 human synovial sarcoma tumors – one…

Teresa Belluco: A Legacy of Hope and Impact
Teresa BellucoCHOP
January 2, 2025

Teresa Belluco: A Legacy of Hope and Impact

Teresa Belluco was just 13 years old when she received a devastating diagnosis—synovial sarcoma, a rare and aggressive cancer that…

Read more
1 … 5 6 7